Population pharmacokinetics and pharmacodynamics of zidovudine in HIV-infected infants and children.
about
Innovative clinical trial design for pediatric therapeuticsGetting to 90-90-90 in paediatric HIV: What is needed?Population pharmacokinetics of abacavir in pregnant women.Maternal and fetal zidovudine pharmacokinetics during pregnancy and labour: too high dose infused at labour?Plasma and intracellular tenofovir pharmacokinetics in the neonate (ANRS 12109 trial, step 2)Population pharmacokinetic studies in pediatrics: issues in design and analysis.The physical and psychological effects of HIV infection and its treatment on perinatally HIV-infected childrenHigh levels of zidovudine (AZT) and its intracellular phosphate metabolites in AZT- and AZT-lamivudine-treated newborns of human immunodeficiency virus-infected mothersPopulation pharmacokinetics study of recommended zidovudine doses in HIV-1-infected childrenThe allometric exponent for scaling clearance varies with age: a study on seven propofol datasets ranging from preterm neonates to adults.A review of nucleoside reverse transcriptase inhibitor use to prevent perinatal transmission of HIV.Pharmacokinetics of zidovudine dosed twice daily according to World Health Organization weight bands in Ugandan HIV-infected children.Pharmacokinetic optimization of antiretroviral therapy in children and adolescents.Antiretroviral drugs in pediatric HIV-infected patients: pharmacokinetic and practical challenges.Optimising the management of fever and pain in children.Liquid chromatography-mass spectrometry methods for the intracellular determination of drugs and their metabolites: a focus on antiviral drugs.A Physiologically-Based Pharmacokinetic Model to Predict Human Fetal Exposure for a Drug Metabolized by Several CYP450 Pathways.Role of ABCB1, ABCG2, ABCC2 and ABCC5 transporters in placental passage of zidovudine.
P2860
Q24635308-F9AD2EB8-F6CA-4535-B3EE-B8695D68552AQ30385352-CA1ED631-46EC-428A-88CE-1EE94DD95E09Q34299084-95DF5AFD-554E-4139-8613-DBD0B68E99C5Q34635561-26C966D3-BE8F-4C30-9941-2449E3C52A5FQ35005051-51F80850-FFB1-48EA-BADA-105A332CFDEEQ36341632-F26E5797-4B67-4A2C-A76E-45E05C00F10FQ36349683-76A145D3-4AB7-4863-B6D2-6A84D112C83EQ36744874-218D51EA-0FC4-48DC-96D5-CEE4C4E4D598Q37263890-022B214A-F0C6-4F19-9CB4-1047FDCE94CBQ37492046-40C26D1B-B832-4D59-830E-83522191D20EQ37588728-60743996-3C88-4207-80BC-6DB6D13D3ABDQ37708677-300E914E-59CE-461F-962A-5A4E940C4F54Q37835819-C789C1CB-0C55-436D-A138-B68204FAEC0BQ37866289-489ED3CF-4533-4B5F-8C6E-78EF500B0F98Q38060826-ACA16627-862F-405D-AB7E-348760CF64A0Q39434360-0B8AA982-DAE3-4B01-B653-50CEDA7BC3A8Q48072950-AC834E10-342C-41EF-9B35-522582975943Q53816970-CA8F0304-5611-4635-ABE6-4E5E9A0B902C
P2860
Population pharmacokinetics and pharmacodynamics of zidovudine in HIV-infected infants and children.
description
2003 nî lūn-bûn
@nan
2003年の論文
@ja
2003年学术文章
@wuu
2003年学术文章
@zh-cn
2003年学术文章
@zh-hans
2003年学术文章
@zh-my
2003年学术文章
@zh-sg
2003年學術文章
@yue
2003年學術文章
@zh
2003年學術文章
@zh-hant
name
Population pharmacokinetics an ...... infected infants and children.
@en
Population pharmacokinetics an ...... infected infants and children.
@nl
type
label
Population pharmacokinetics an ...... infected infants and children.
@en
Population pharmacokinetics an ...... infected infants and children.
@nl
prefLabel
Population pharmacokinetics an ...... infected infants and children.
@en
Population pharmacokinetics an ...... infected infants and children.
@nl
P2093
P2860
P356
P1476
Population pharmacokinetics an ...... infected infants and children.
@en
P2093
Carol J Baker
Edmund V Capparelli
James D Connor
Janet A Englund
Paul Palumbo
Ross E McKinney
Stephen A Spector
P2860
P304
P356
10.1177/0091270002239821
P577
2003-02-01T00:00:00Z